Acumen Pharmaceuticals Stock Short Ratio
| ABOS Stock | USD 1.08 0.02 1.82% |
Fundamental analysis of Acumen Pharmaceuticals allows traders to better anticipate movements in Acumen Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Acumen | Short Ratio | Build AI portfolio with Acumen Stock |
Acumen Pharmaceuticals Company Short Ratio Analysis
Acumen Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Acumen Pharmaceuticals Short Ratio | 8.07 X |
Most of Acumen Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acumen Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as Short Ratio. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Acumen Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Acumen Pharmaceuticals has a Short Ratio of 8.07 times. This is 106.92% higher than that of the Biotechnology sector and 8.91% higher than that of the Health Care industry. The short ratio for all United States stocks is 101.75% lower than that of the firm.
Acumen Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in short ratio category among its peers.
Acumen Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Acumen Pharmaceuticals from analyzing Acumen Pharmaceuticals' financial statements. These drivers represent accounts that assess Acumen Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Acumen Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 763.3M | 151.4M | 89.3M | 96.3M | 110.8M | 105.2M |
Acumen Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acumen Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acumen Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acumen Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2024-12-31 | 870.6 K | Laurion Capital Management Lp | 2024-12-31 | 867 K | Hudson Bay Capital Management Lp | 2024-12-31 | 715 K | Pathstone Holdings Llc | 2024-12-31 | 606.8 K | State Street Corp | 2024-12-31 | 525.8 K | Two Sigma Advisers, Llc | 2024-12-31 | 499.1 K | Northern Trust Corp | 2024-12-31 | 307.6 K | Two Sigma Investments Llc | 2024-12-31 | 301.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 266.2 K | Ra Capital Management, Llc | 2024-12-31 | 14.9 M | Sands Capital Ventures, Llc | 2024-12-31 | 3.4 M |
Acumen Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | (76.19 M) | ||||
| Shares Outstanding | 60.57 M | ||||
| Shares Owned By Insiders | 11.14 % | ||||
| Shares Owned By Institutions | 75.91 % | ||||
| Number Of Shares Shorted | 1.76 M | ||||
| Price To Book | 0.37 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (93.8 M) | ||||
| EBITDA | (98.08 M) | ||||
| Net Income | (102.33 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 28.73 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 3.03 X | ||||
| Cash Flow From Operations | (86.22 M) | ||||
| Short Ratio | 8.07 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 9.2 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.098 | ||||
| Market Capitalization | 66.63 M | ||||
| Total Asset | 238.99 M | ||||
| Retained Earnings | (325.13 M) | ||||
| Working Capital | 150.7 M | ||||
| Net Asset | 238.99 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.